Sign in

BGM on Nasdaq

BGM Group Ltd.

BGM Group Ltd. is a pharmaceutical preparations company in the Cayman Islands.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$37.9MRevenue, fiscal 20252
-$19.9MNet income, fiscal 20252

Compare with LFTD PARTNERS INC., Sunshine Biopharma Inc. or Enveric Biosciences, Inc., or pick any stock.

  • TickerBGM on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersE91
  • Incorporated inCayman Islands3
  • Business addressNo. 152 Hongliang East 1St Street, No. 1703, Tianfu New District, Chengdu, 00003
  • Filer categoryNon-accelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

BGM Group Ltd is not a Chinese operating company but a Cayman Islands holding company with its business operations conducted by Gansu Qilianshan Pharmaceutical Co., Ltd. (the “VIE”, “Gansu QLS”) and its subsidiaries established in the PRC. BGM Group Ltd (formerly known as Qilian International Holding Group Limited) is a Cayman Islands exempted company with limited liability incorporated on February 7, 2019. Qilian International (Hong Kong) Holdings Limited., which we refer to as “Qilian HK”, our wholly-owned subsidiary, was incorporated in Hong Kong on January 30, 2019. Qilian HK’s wholly owned subsidiary, Qilian International Trading (Chengdu) Co., Ltd., formerly known as Chengdu Qilian Trading Co., Ltd., which we refer to as “WFOE”, was organized pursuant to PRC laws on May 15, 2019. Gansu Qilianshan Pharmaceutical Co. Ltd., which we refer to as Gansu QLS, the VIE, was established in A…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

16.6%Gross margin2
-33.2%Operating margin2
-52.6%Net margin2
51.1%Revenue growth, 20252
-5.1%Return on equity2
-$3.9MFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Diversified Pharmaceutical and Allied Products brought in 62% of the revenue BGM Group Ltd. broke down this way in fiscal 2025.

  1. Diversified Pharmaceutical and Allied Products$23.6M262%down 6% from 2024
  2. Insurance Business$11.0M229%
  3. AI Solutions$3.4M29%
Business segments by year
Business segments202320242025
Diversified Pharmaceutical and Allied Products$46.5M$25.1M$23.6M
Insurance Business$11.0M
AI Solutions$3.4M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue62¢$31.6M
  • Research and development1¢$672.7K
  • Selling, general and admin36¢$18.2M
  • Income tax1¢$277.8K

Out of $37.9M in revenue.2 The company lost money this year.

Financial statements

Revenue567892$37.9M in 2025−25% since 2018
0$20.0M$40.0M$60.0M$80.0M2018: $50.4M$50.4M20182019: $46.1M$46.1M2019−8%2020: $50.0M$50.0M2020+9%2021: $57.1M$57.1M2021+14%2022: $64.9M$64.9M2022+14%2023: $46.5M$46.5M2023−28%2024: $25.1M$25.1M2024−46%2025: $37.9M$37.9M2025+51%
Gross profit567892$6.3M in 2025−22% since 2018
0$2.5M$5.0M$7.5M$10.0M2018: $8.1M$8.1M20182019: $9.7M$9.7M2019+19%2020: $7.5M$7.5M2020−22%2021: $5.6M$5.6M2021−25%2022: $6.2M$6.2M2022+10%2023: $1.8M$1.8M2023−72%2024: $4.1M$4.1M2024+135%2025: $6.3M$6.3M2025+53%
Operating income567892-$12.6M in 2025
-$15.0M-$10.0M-$5.0M0$5.0M$10.0M2018: $6.0M$6.0M20182019: $6.2M$6.2M2019+3%2020: $4.8M$4.8M2020−22%2021: $2.4M$2.4M2021−50%2022: $2.1M$2.1M2022−12%2023: -$2.6M-$2.6M20232024: -$563.8K-$563.8K2024−78%2025: -$12.6M-$12.6M2025+2132%
Net income567892-$19.9M in 2025
-$20.0M-$10.0M0$10.0M2018: $5.2M$5.2M20182019: $5.9M$5.9M2019+14%2020: $5.1M$5.1M2020−14%2021: $3.2M$3.2M2021−38%2022: $1.1M$1.1M2022−66%2023: -$7.8M-$7.8M20232024: -$1.4M-$1.4M2024−81%2025: -$19.9M-$19.9M2025+1282%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-09-302024-09-302023-09-30
NET REVENUE$37.9M$25.1M$46.5M
COST OF REVENUE$31.6M$21.0M$44.7M
GROSS PROFIT$6.3M$4.1M$1.8M
SELLING, GENERAL AND ADMINISTRATIVE$18.2M$3.3M$3.8M
RESEARCH AND DEVELOPMENT EXPENSES$672.7K$1.4M$568.5K
LOSS FROM OPERATIONS-$12.6M-$563.8K-$2.6M
Interest income (expense), net$83.1K-$639.5K$99.2K
Investment loss-$7.7M-$819.4K-$5.5M
Loss on disposal of long term investment-$101.4K
Share of results of associates-$427.7K-$204.6K
Grant income$132.3K$206.4K$192.4K
Other Income (expenses)$555.0K-$14.8K-$61.0K
Total other expense-$7.4M-$1.6M-$5.3M
LOSS BEFORE INCOME TAX PROVISION-$19.9M-$2.1M-$7.9M
INCOME TAX EXPENSE/(BENEFIT)$277.8K-$620.0K$219.2K
NET LOSS-$20.2M-$1.5M-$8.1M
Less: net loss attributable to non-controlling interest-$274.8K-$74.3K-$341.4K
NET LOSS ATTRIBUTABLE TO BGM Group Ltd.-$19.9M-$1.4M-$7.8M
Foreign currency translation adjustment$3.8M$1.3M-$730.9K
COMPREHENSIVE LOSS-$16.4M-$258.1K-$8.9M
Less: comprehensive loss attributable to non - controlling interests-$330.1K-$210.2K-$381.4K
COMPREHENSIVE LOSS ATTRIBUTABLE TO BGM Group Ltd.-$16.1M-$47.9K-$8.5M
Earnings (loss) per common share - basic (in dollar per share)-$0.18-$0.20-$1.08
Earnings (loss) per common share - diluted (in dollar per share)-$0.18-$0.20-$1.08
Weighted average shares - basic (in shares)113.3M shares7.2M shares7.2M shares
Weighted average shares - diluted (in shares)113.3M shares7.2M shares7.2M shares

Compare BGM Group Ltd. with another company

Corporate structure

BGM Group Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BGM Group Ltd.

  • Sihai Ban Filed SCHEDULE 13G on BGM Group Ltd., latest May 28, 2025
  • Xing Lai Filed SCHEDULE 13G on BGM Group Ltd., latest May 28, 2025
  • AIFU Inc. Filed SCHEDULE 13D/A on BGM Group Ltd., latest May 27, 2025 (2 filings since Jan 6, 2025)
  • Thia Yang Low Filed SCHEDULE 13D on BGM Group Ltd., latest May 27, 2025
  • Zefei Lou Filed SCHEDULE 13G on BGM Group Ltd., latest May 6, 2025
  • Zhuojun Feng Filed SCHEDULE 13G on BGM Group Ltd., latest May 6, 2025
  • LX Management Co Ltd Filed SC 13D on BGM Group Ltd., latest Dec 3, 2024
  • Ahanzhai Development Ltd Filed SC 13D/A on BGM Group Ltd., latest Nov 29, 2024 (2 filings since Oct 16, 2024)
  • BGM Group Ltd. E9

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BGM Group Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Construction in progress$4.0M2 Sep 30, 2025$5.6M2 Sep 30, 2024−28.5%
Operating-lease assets (leased space)$316.0K2 Sep 30, 2025$59.3K9 Sep 30, 2023+432.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$9.8M2 Sep 30, 2025$9.8M2 Sep 30, 20240%
Stakes in other companies (equity method)$11.5M2 Sep 30, 2025$3.4M2 Sep 30, 2024+242.1%
Long-term investments$11.5M2 Sep 30, 2025$3.4M2 Sep 30, 2024+242.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$350.8M2 Sep 30, 2025
Intangible assets, net (excluding goodwill)$4.5M2 Sep 30, 2025$4.5M2 Sep 30, 2024−1.1%
Finite-lived intangibles, gross$10.6M2 Sep 30, 2025$5.4M2 Sep 30, 2024+96.2%
Accumulated amortization$6.1M2 Sep 30, 2025$862.9K2 Sep 30, 2024+608.5%
Finite-lived intangibles, net$4.5M2 Sep 30, 2025$4.5M2 Sep 30, 2024−1.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$20.1M2 Sep 30, 2025$5.0M2 Sep 30, 2024+298.1%
Work in process$326.8K2 Sep 30, 2025$400.3K2 Sep 30, 2024−18.3%
Finished goods$12.5M2 Sep 30, 2025$2.3M2 Sep 30, 2024+438.4%

Leadership

Who has led BGM Group Ltd., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Yaxuan Zhai2026–now
Board members and other officers (3)

Former names

  • Qilian International Holding GroupOct 22, 2024 to Oct 22, 20243
  • Qilian International Holding Group LtdJun 17, 2019 to Oct 16, 20243

Filings

111 filings to the SEC since October 2021: 11 annual reports, 5 insider forms, 10 large holders, 85 other. The latest 20:

  1. Sep 24, 20266-K EDGAR
  2. Sep 8, 20266-K EDGAR
  3. Aug 28, 20266-K EDGAR
  4. Aug 11, 20266-K EDGAR
  5. Jul 30, 20266-K EDGAR
  6. Jul 28, 20266-K EDGAR
  7. Jul 21, 202620-F EDGAR
  8. Jul 13, 20266-K EDGAR
  9. Jun 17, 20266-K EDGAR
  10. Jun 9, 20266-K EDGAR
  11. May 18, 20266-K EDGAR
  12. May 14, 20263 OWNERSHIP DOCUMENT EDGAR
  13. May 14, 20263 OWNERSHIP DOCUMENT EDGAR
  14. May 14, 20263 OWNERSHIP DOCUMENT EDGAR
  15. May 14, 20263 OWNERSHIP DOCUMENT EDGAR
  16. May 7, 20266-K EDGAR
  17. Apr 30, 20266-K EDGAR
  18. Apr 13, 20263 PRIMARY DOCUMENT EDGAR
  19. Jan 30, 2026NT 20-F EDGAR
  20. Jan 29, 20266-K EDGAR

The 111 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Sihai BanSCHEDULE 13G, 1 filing May 28, 202514
  • Xing LaiSCHEDULE 13G, 1 filing May 28, 202515
  • AIFU Inc.SCHEDULE 13D/A, 2 filings Jan 6, 2025 to May 27, 202516
  • Thia Yang LowSCHEDULE 13D, 1 filing May 27, 202517
  • Zefei LouSCHEDULE 13G, 1 filing May 6, 202518
  • Zhuojun FengSCHEDULE 13G, 1 filing May 6, 202519
  • LX Management Co LtdSC 13D, 1 filing Dec 3, 202420
  • Ahanzhai Development LtdSC 13D/A, 2 filings Oct 16, 2024 to Nov 29, 202421

SEC filer profile

How BGM Group Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBGM Group Ltd.1
  • CIK0001779578
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsSeptember 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressNo. 152 Hongliang East 1St Street, No. 1703, Tianfu New District, Chengdu, Chengdu 0000, China1
  • Phone86-028-647751801
  • Shares outstanding200,623,358 Common Stock shares; 180,623,358 Common Class A shares; 20,000,000 Common Class B shares as of Sep 30, 20254
  • AuditorEnrome LLP, Singapore PCAOB ID 6907; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJun 17, 20191
  • Filings154 in all: 6-K (56), CORRESP (16), UPLOAD (16), F-1/A (9), 20-F/A (7), 20-F (6), 3 (5), EFFECT (4)1
    All 27 form types

    FWP (4), NT 20-F (4), SCHEDULE 13G (4), F-3 (3), SC 13G (3), S-8 (2), SC 13D (2), SCHEDULE 13D (2), 424B4 (1), 6-K/A (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), F-1 (1), F-3/A (1), SC 13D/A (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (20-F) Jul 21, 2026

Securities registered for trading

ClassSymbolExchange
Class A Ordinary SharesBGMNasdaq

From the cover page of the 20-F filed Jul 21, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21